In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

@article{Draghi2008InVA,
  title={In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.},
  author={Deborah C. Draghi and Bret M Benton and Kevin M. Krause and Clyde Thornsberry and Chris M. Pillar and Daniel F. Sahm},
  journal={The Journal of antimicrobial chemotherapy},
  year={2008},
  volume={62 1},
  pages={116-21}
}
OBJECTIVES Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel. METHODS Gram-positive clinical isolates, collected between October 2004 and December 2005 from 36 hospital… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…